RxDoctor Payments Data

Catherine Hanneman, PA

Physician Assistant · Augusta, GANPI 1013791706

Payments from drug & device makers

$7,780in general payments, 2019–2025

Across 314 payments — averaging $24.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$1K
  • AbbVie$1K
  • Novartis$598
  • AstraZeneca$461
  • Merck$445
  • Johnson & Johnson$439
  • plus $3K from 50 others

What the payments were for

  • Food & beverage$7,780100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,780 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$27,612
Medicare patients
125
Services billed
931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab20$138,585
Enbrel SureclickEtanercept14$123,087
BenlystaBelimumab17$117,078
RasuvoMethotrexate/Pf11$6,033
Hydroxychloroquine Sulfate166$4,507
MethotrexateMethotrexate Sodium207$3,536
Celecoxib37$1,494
Prednisone244$973
Azathioprine34$713
Febuxostat15$595
Leflunomide19$503
Sulfasalazine27$302
Sulfasalazine DrSulfasalazine15$291
Methotrexate SodiumMethotrexate Sodium/Pf19$180
Folic Acid14$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$408$117,07817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →